Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
E. Papazoglou (Larissa, Greece), R. Jagirdar (Larissa, Greece), E. Pitaraki (Larissa, Greece), O. Kotsiou (Larissa, Greece), C. Hatzoglou (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), S. Zarogiannis (Larissa, Greece). Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells. 2895

Member's Comments

No comment yet.

Related content which might interest you: Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Biological characteristics of dendritic cells from malignant pleural effusions in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Effects of Cisplatin and Pemetrexed on the cell viability and cell adhesion of benign mesothelial and mesothelioma cells. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Pleural atypical mesothelial hyperplasia: An early stage of pleural malignant mesothelioma? Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Hypotonic carboplatin pleurodesis for malignant pleural effusion of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Multimodality therapy for malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002